Literature DB >> 11391850

Measured versus estimated glomerular filtration rate in the Calvert equation: influence on carboplatin dosing.

A Donahue1, J S McCune, S Faucette, H H Gillenwater, R J Kowalski, M A Socinski, C Lindley.   

Abstract

PURPOSE: Carboplatin is frequently dosed to achieve a desired area under the plasma concentration-time curve (AUC) by using the Calvert or Chatelut equations to estimate carboplatin clearance. Accurate determination of glomerular filtration rate (GFR) is necessary to correctly calculate carboplatin clearance using the Calvert equation. In clinical practice, the Cockcroft-Gault formula is frequently used to estimate GFR, but this practice has been reported to under- and overestimate carboplatin clearance. The purpose of this trial was to compare determinations of carboplatin clearance using the Chatelut equation and four separate GFR determinations, including 99mTc-DTPA, the Cockcroft-Gault formula, a 24-h urine collection and a 2-h urine collection.
METHODS: Carboplatin clearance was estimated in 21 previously untreated extensive-stage small-cell lung cancer patients. GFR was determined using 99mTc-DTPA, the Cockcroft-Gault formula, 24-h urine collection and 2-h urine collection. Serum and urine creatinine concentrations were measured using enzymatic assays. The carboplatin clearance was then calculated by individually adding 25 to the four GFR determinations based on the Calvert equation, which states that carboplatin clearance equals GFR + 25 (nonrenal clearance). The carboplatin clearance was also estimated using the Chatelut equation. The five determinations of carboplatin clearance were compared using Friedman's test and post-hoc Wilcoxon signed rank tests. Precision and bias for each carboplatin clearance determination were calculated assuming that 99mTc-DTPA provided the most accurate measure of GFR.
RESULTS: A statistically significant difference was found between the five methods of estimating carboplatin clearance (P < 0.001). No difference was found between carboplatin clearance calculated using 99mTc-DTPA and the Chatelut equation, the Cockcroft-Gault formula or the 2-h urine collection. The Chatelut equation provided more precision and less bias than the 2-h urine collection (median precision 20% and 30%, median bias -1% and -18%, respectively).
CONCLUSION: Compared to 99mTc-DTPA, the Chatelut equation more accurately estimates carboplatin clearance than the Cockcroft-Gault formula, the 2-h urine collection and the 24-h urine collection. The greater negative bias found for the latter three estimates of carboplatin clearance could result in underdosing of carboplatin.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11391850     DOI: 10.1007/s002800000260

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  7 in total

1.  Comparison of two methods for carboplatin dosing in children with retinoblastoma.

Authors:  Steven Allen; Matthew W Wilson; Amy Watkins; Catherine Billups; Ibrahim Qaddoumi; Barrett H Haik; Carlos Rodriguez-Galindo
Journal:  Pediatr Blood Cancer       Date:  2010-07-15       Impact factor: 3.167

2.  Sobh formula: a new formula for estimation of creatinine clearance in healthy subjects and patients with chronic renal disease.

Authors:  Mohamed Sobh; Ahmed Neamatallah; Hussein Sheashaa; Ahmed Akl; Yasser Osman; Hossam Gad; Mohamed Eletrby; Ahmed Hegazy
Journal:  Int Urol Nephrol       Date:  2005       Impact factor: 2.370

3.  Angiotensin-converting enzyme inhibitors predict acute kidney injury during chemoradiation for head and neck cancer.

Authors:  Michael T Spiotto; Hongyuan Cao; Loren Mell; F Gary Toback
Journal:  Anticancer Drugs       Date:  2015-03       Impact factor: 2.248

4.  Safety and tolerability of docetaxel, cyclophosphamide, and trastuzumab compared to standard trastuzumab-based chemotherapy regimens for early-stage human epidermal growth factor receptor 2-positive breast cancer.

Authors:  Potjana Jitawatanarat; Tracey L O'Connor; Ellen B Kossoff; Ellis G Levine; Kaweesak Chittawatanarat; Nuttapong Ngamphaiboon
Journal:  J Breast Cancer       Date:  2014-12-26       Impact factor: 3.588

5.  Switching from standard to dose-dense chemotherapy in front-line treatment of advanced ovarian cancer: a retrospective study of feasibility and efficacy.

Authors:  Andrea Milani; Rebecca Kristeleit; Mary McCormack; Fharat Raja; Daniela Luvero; Martin Widschwendter; Nicola MacDonald; Tim Mould; Adeola Olatain; Allan Hackshaw; Jonathan A Ledermann
Journal:  ESMO Open       Date:  2017-01-31

Review 6.  Pharmacological factors influencing anticancer drug selection in the elderly.

Authors:  Veena John; Sandeep Mashru; Stuart Lichtman
Journal:  Drugs Aging       Date:  2003       Impact factor: 4.271

7.  Cost-effectiveness of paclitaxel, doxorubicin, cyclophosphamide and trastuzumab versus docetaxel, cisplatin and trastuzumab in new adjuvant therapy of breast cancer in china.

Authors:  Qiaoping Xu; Li Yuanyuan; Zhu Jiejing; Liu Jian; Li Qingyu; Chen Lingya; Luo Ying; Shi Changchen; Li Yangling; Yan Wei
Journal:  Cost Eff Resour Alloc       Date:  2021-02-23
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.